Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care
Using target trial emulation, real-world OS is similar with palbociclib/ribociclib/abemaciclib plus AI. These findings may contribute to the development of combination strategies to improve clinical outcomes and to guide clinical decision-making.
Authors
- Jessica Davies
- A Brufsky
- Otto Metzger
- A A Grigorenko
- Gráinne H. Long (ORCID: https://orcid.org/0000-0001-5080-9885)
- Sameet Sreenivasan
- Rodrigo Goncalves
- Ula Nur
- Richard S. Finn
- Cynthia Huang-Bartlett
Institutions
- University of California, Los Angeles (US)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- University of Pittsburgh Medical Center (US)
- AstraZeneca (Spain) (ES)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1007/s10549-026-07935-3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca